Bionano Genomics announced that its Chinese original equipment manufacturing, or OEM, partner, A-smart MedTech, or A-smart, an assisted reproductive technology company, has obtained reagent class I registrations from China’s National Medical Products Administration, or NMPA, for Bionano’s DNA extraction kit and labeling products. A-smart is Bionano’s second Chinese OEM partner to obtain approval from NMPA for the Company’s optical genome mapping, or OGM, solutions. NMPA issued two approvals to A-smart: one for Bionano’s G2 direct label and stain, or DLS, DNA labeling kit and one for Bionano’s G2 SP bone marrow aspirate, or BMA, DNA isolation kit. A-smart received IVD Class I labels, enabling these reagents to be used for in vitro diagnostics in China.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNGO:
- Bionano Genomics regains compliance with Nasdaq’s minimum bid price requirement
- Bionano Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
- Bionano Genomics receives CAP accreditation for clinical laboratory
- Bionano Laboratories Receives College of American Pathologists (CAP) Accreditation for its Clinical Laboratory
- Bionano Genomics announces CFO transition, appointment of Kama as CFO